Integrin-Linked Kinase Overexpression and Its Oncogenic Role in Promoting Tumorigenicity of Hepatocellular Carcinoma by Chan, Jenny et al.
Integrin-Linked Kinase Overexpression and Its
Oncogenic Role in Promoting Tumorigenicity of
Hepatocellular Carcinoma
Jenny Chan
1, Frankie Chi Fat Ko
1,2, Yin-Shan Yeung
1, Irene Oi-Lin Ng
1,3,4, Judy Wai Ping Yam
1,2,3*
1Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China, 2Centre for Cancer Research, Li Ka Shing Faculty of
Medicine, The University of Hong Kong, Hong Kong, China, 3State Key Laboratory for Liver Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong
Kong, China, 4Liver Cancer and Hepatitis Research Laboratory, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Abstract
Background: Integrin-linked kinase (ILK) was first discovered as an integrin b1-subunit binding protein. It localizes at the
focal adhesions and is involved in cytoskeleton remodeling. ILK overexpression and its dysregulated signaling cascades have
been reported in many human cancers. Aberrant expression of ILK influenced a wide range of signaling pathways and
cellular functions. Although ILK has been well characterized in many malignancies, its role in hepatocellular carcinoma (HCC)
is still largely unknown.
Methodology/Principal Findings: Quantitative PCR analysis was used to examine ILK mRNA expression in HCC clinical
samples. It was shown that ILK was overexpressed in 36.9% (21/57) of HCC tissues when compared to the corresponding
non-tumorous livers. The overall ILK expression level was significantly higher in tumorous tissues (P=0.004), with a
significant stepwise increase in expression level along tumor progression from tumor stage I to IV (P=0.045). ILK
knockdown stable clones were established in two HCC cell lines, BEL7402 and HLE, and were subjected to different
functional assays. Knockdown of ILK significantly suppressed HCC cell growth, motility and invasion in vitro and inhibited
tumorigenicity in vivo. Western blot analysis revealed a reduced phosphorylated-Akt (pAkt) at Serine-473 expression in ILK
knockdown stable clones when compared to control clones.
Conclusion/Significance: This study provides evidence about the clinical relevance of ILK in hepatocarcinogenesis. ILK was
found to be progressively elevated along HCC progression. Here our findings also provide the first validation about the
oncogenic capacity of ILK in vivo by suppressing its expression in HCC cells. The oncogenic role of ILK is implicated to be
mediated by Akt pathway.
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Introduction
HCC is the fifth most common cancer worldwide and highly
prevalent in southeastern Asia [1]. It displays late diagnosis, poor
prognosis and high mortality rate. There is currently no effective
treatment for HCC. Only approximately 15% of patients are
eligible for tumor resection or liver transplantation, where half of
them will experience tumor recurrence 3 years after therapy [2,3].
HCC is a highly complicated and heterogeneous tumor which
results from the aberrant activation of numerous important
signaling pathways. Understanding the molecular mechanisms of
HCC is of the utmost importance to the search for curative
therapy.
ILK was first discovered in 1996 by Hannigan et al. in a yeast-
two hybrid experiment screening for integrin b1-subunit interactor
[4]. Since then, a large number of studies have been conducted on
ILK, attempting to understand the expression and functional roles
of ILK in the cells. The ILK gene is located at human
chromosome 11, band 11p15.4/15.5. Database searches found
that only one ILK gene exists [5]. The ILK protein consists of 452
amino acids and is made up of three major domains – the N-
terminal ankyrin repeats, middle pleckstrin homology (PH)
domain and C-terminal kinase domain. The major role of ILK
is to act as an adaptor protein which allows various intracellular
proteins to interact directly with its three domains [6]. The kinase
domain is shown to phosphorylate key signaling players such as
Akt and GSK3b [7]. ILK has been well characterized to be an
important player in the focal adhesions. For example, it physically
interacts with cytoplasmic proteins PINCH and parvins to form
the PINCH-ILK-parvin (PIP) complex, which helps to translocate
ILK to the focal adhesions upon activation by the ECM-
stimulated integrin receptors [8,9]. ILK is also involved in
regulating actin polymerization along with its well-characterized
scaffolding role in the focal adhesions.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16984ILK expression and its oncogenic potentials have been studied
in various malignancies. Immunohistochemistry (IHC) revealed a
higher ILK expression in primary prostate cancer with respect to
the adjacent benign prostate hyperplasia. Its expression also
positively correlated with tumor grade while inversely correlated
with the 5-year survival rate [10]. Similarly, IHC on 53 ovarian
cancer samples showed a 100% positive signal, while no stain was
observed in normal ovarian epithelium. The staining intensity was
observed to increase with tumor grade [11]. ILK has also been
shown to have implication in colon cancer progression that higher
ILK expression was detected in metastatic tumor and was
increased with tumor stage, grade and invasiveness [12]. All these
compelling evidences have demonstrated the oncogenic effect of
ILK in cancer development. In addition, ILK was reported to be
overexpressed in HCC and cirrhosis [13,14]. Nevertheless,
functional characterization of ILK in HCC is still lacking. In this
study, we elucidated the role of ILK in hepatocarcinogenesis by
assessing its expression in human HCC tumor samples and
functionally characterizing its role in HCC cell models. We found
that ILK was indeed overexpressed in HCC and exerted
oncogenic effect on HCC cell lines both in vitro and in vivo.
Results
ILK overexpression was detected in HCC and correlated
significantly with HCC tumor grade
Quantitative PCR was used to examine the transcript level of
ILK in 57 paired HCC tumor samples, each of which consisted of
the tumor (T) tissue and the adjacent non-tumorous (NT) liver.
Cases with T/NT ratio greater than 2 were classified as
overexpression. ILK was found to be overexpressed in 36.9%
(21/57) of the cases. When compared the overall ILK expression
levels, ILK transcript level was significantly higher in tumor tissues
than in non-tumorous liver (P=0.004, unpaired t-test) (Fig. 1A).
HCC tumor stage was classified using the Tumor-Node-Metastasis
(pTNM) staging system. Stage I and II were regarded as early
stage while stage III and IV were advanced stage. There was no
significant difference in ILK expression level between cirrhotic
liver and stage I tumor. However, Fig. 1B revealed a stepwise
increase in ILK expression across tumor stages, namely stage I &
II, stage III and stage IV. Notably, ILK expression level was
significantly higher in stage IV when compared with cirrhotic liver
and early stage HCC (P=0.013 and P=0.045, respectively). This
result suggests ILK expression was progressively increases during
HCC progression.
Knockdown of ILK suppressed HCC cell growth
One effective way to understand the physiological role of ILK in
HCC was to inhibit the expression of endogenous ILK in HCC
cell line models. Western blot analysis of ILK expression in a panel
of HCC cell lines revealed that ILK expression in all HCC cell
lines was higher than that in MIHA, an immortalized non-
tumorigenic liver cell line (Fig. 1C). Efficient knockdown of ILK
expression was achieved by the successful delivery and expression
Figure 1. ILK expression was elevated in HCC clinical samples
and cell lines. (A) ILK mRNA expression was examined by qPCR. ILK
was overexpressed in 36.9% of the HCC samples. Cases with T/NT ratio
.2 were classified as overexpression, while those with T/NT ratio ,0.5
were regarded as underexpression. The remaining cases with 0.5, ratio
,2 were regarded as no change in ILK expression. Higher ILK
expression (P=0.004) was observed in tumor samples when compared
to their non-tumor counterparts. (B) A stepwise increase of ILK
expression along HCC tumor stage was observed. (C) ILK expression
in a panel of HCC cell lines was analyzed by western blot analysis. MIHA
is an immortalized non-tumorigenic liver cell line. Relative ILK
expression normalized with corresponding b-actin expression was
shown below.
doi:10.1371/journal.pone.0016984.g001
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a lentiviral-based delivery system was used to introduce and
express two specific ILK shRNA targeting sequences in two HCC
cell lines, namely BEL7402 and HLE. Two ILK knockdown stable
clones E5 and E6, as well as one non-targeted knockdown control
NT were established in BEL7402 (Fig. 2A). With reference to NT,
a higher ILK knockdown efficiency was achieved in E6 than in E5.
Compared with the ILK expression level in NT, 6.8% and 64.2%
Figure 2. Knockdown of ILK in HCC cell lines impaired HCC cell proliferation and anchorage independent growth. (A) One sh-non-
target control clone (NT) and two ILK knockdown stable clones were established in BEL7402 (E5, E6) and HLE (E5, E7). (B) shILK sequence E6 showed a
higher knockdown efficiency than E5 in BEL7402, while both E5 and E7 showed similar knockdown effect in HLE. (C and D) Numbers of cells in
BEL7402 and HLE ILK knockdown stable clones were counted in triplicates for 5 to 8 consecutive days. Growth curves were plotted to reveal the
growth pattern of each cell line. (E) Cells from BEL7402 ILK knockdown stable clones were grown in soft agar for 1 month. Colonies were formed from
single cells and the number of colonies with diameter .60 mm were counted under microscope. (F) Colonies formed from HLE ILK knockdown stable
clones were also counted and plotted. Representative pictures of colonies formed from each knockdown stable clone were shown. Asterisk (*)
indicates a P-value ,0.05 with significant difference between NT control and ILK knockdown clones (E5, E6 and E7).
doi:10.1371/journal.pone.0016984.g002
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(Fig. 2B). Similarly, three knockdown stable clones, NT, E5 and
E7 were established in HLE (Fig. 2A). Both E5 and E7 clones
displayed about 60% knockdown efficiency compared to the
control (Fig. 2B).
To determine the effect of ILK expression on HCC cell growth,
proliferation curves of the ILK knockdown stable clones and the
corresponding non-targeted control were determined and com-
pared. As shown in Fig. 2C, similar proliferation rates were
observed for BEL7402 NT, E5 and E6 during the first 3 days.
However, starting from day 4, a significant difference in cell
growth was observed between the two ILK knockdown clones and
the non-targeted control. NT was found to have a higher
proliferation rate when compared to E5 and E6, and this trend
persisted till the last day of the proliferation assay. Similar result
was observed in HLE ILK knockdown stable clones (Fig. 2D).
Both ILK knockdown stable clones, E5 and E7, showed a decrease
in proliferation when compared to NT starting from day 2. It was
also noted that the ILK knockdown efficiency correlated well with
the growth suppression effect in both HCC cell lines. Stable clones
with better ILK knockdown effect displayed a lower proliferation
rate. Results here suggested that ILK knockdown suppressed cell
proliferation of HCC cells.
Soft agar colony formation assay was used to assess the ILK
knockdown effect on the anchorage independent growth of HCC
cells. It was found that single cells seeded were able to form
colonies in all three E5, E6 and NT stable clones established in
BEL7402. Nevertheless, the size of the colonies varied among the
three stable clones. Largest colonies were observed in NT control
clone while colonies found in E5 were in moderate size and those
in E6 were smallest (Fig. 2E). To compare the number of colonies
(with diameter greater than 60 mm) formed, number of colonies
formed in NT control clone was significantly higher than E6
knockdown clone (P=0.041). HLE ILK knockdown stable clones
were also subjected to soft agar colony formation assay. Contrary
to BEL7402 cells, not all single cells seeded formed colonies in
HLE ILK knockdown stable clones (Fig. 2F). The colony number
formed in NT was significantly larger than number of colonies
formed in E5 (P=0.001) and E7 (P=0.044). Consistent results
observed in both BEL7402 and HLE suggested the suppression of
anchorage independent growth on HCC cell lines upon ILK
knockdown.
Knockdown of ILK reduced the migratory and invasive
potentials of HCC cells
To assess the migratory ability of ILK knockdown stable clones,
wound-healing and transwell migration chamber were employed.
For wound-healing assay of BEL7402 ILK knockdown clones, the
wound in NT control clone was almost closed in 72 hours, yet the
wounds in E5 and E6 stable clones were still clearly seen (Fig. 3A).
Differences in wound-closure ability were even more obvious in
HLE ILK knockdown stable clones, in which a difference could be
observed 16 hours after the creation of the wound. Larger wound
was observed in E5 and E7 stable clones when compared with NT
control clone (Fig. 3A). Consistently, the transwell migration assay
revealed that numbers of migrated cells in BEL7402 NT control
clones were significantly higher when compared to E5 (P=0.009)
and E6 (P=0.003) stable clones (Fig. 3B). Also, both E5
(P,0.001) and E7 (P,0.001) stable clones of HLE displayed a
significant reduction in migratory potential when compared with
NT control clones.
Cell invasiveness of ILK knockdown stable clones was assessed
by seeding the cells onto matrigel-coated invasion chamber. For
BEL7402, more invaded cells were observed in NT control and E5
stable clones, while significantly fewer cells were able to invade
through the matrigel in E6 stable clones (P=0.024) (Fig. 3C).
Results of invasion assay performed using HLE ILK knockdown
clones showed a similar outcome. More invaded cells were
observed in NT control clone and significantly fewer cells in E5
(P=0.004) and E7 (P=0.004) stable clones (Fig. 3C). All these
suggested the involvement of ILK in regulating HCC cell motility
and invasiveness and knockdown of it suppressed cell invasion.
Knockdown of ILK impaired HCC cell in vivo
tumorigenicity
Since HLE was unable to form tumor upon subcutaneous
injection, only BEL7402 ILK knockdown stable clones were
subjected to nude mice injection. After subcutaneous injection of
the cells into nude mice, tumor growth was monitored carefully
and the size of the tumor formed was measured weekly. Staring
from week 2, larger tumors were formed from mice injected with
NT control clone, while smaller tumors were formed from E5 and
E6 stable clone (Fig. 4A). At week three, the animals were
sacrificed due to oversize of the tumors (Fig. 4B). Tumors were
then harvested from the mice, photographed and weighed.
Tumors formed from NT control clone were significantly larger
than E5 (P=0.036) and E6 (P=0.008) stable clones. NT tumors
were the largest among the three experimental groups while E6
stable clone developed the smallest tumors. This trend was also
reflected from the weight of the tumors, where the average weight
of tumors from NT control clone was significantly higher than E6
stable clone (P=0.032) (Fig. 4C). This result demonstrated that
suppression of ILK in HCC cells attenuated the ability of HCC
cells to form tumors in nude mice.
ILK overexpression enhanced HCC cell growth and
motility
Apart from knockdown approach, overexpression of ILK in
HCC cells was adopted as a complementary method to
characterize the role of ILK in HCC. HCC cell line PLC was
employed as the working model for overexpression approach due
to its relatively low expression level of endogenous ILK (Fig. 1C).
Stable PLC overexpressing FLAG-ILK clone and vector control
clone were established (Fig. 5A). PLC ILK overexpressing cells
were subjected to proliferation and motility assays. Results
revealed that ILK overexpressing cells displayed significantly
enhanced cell proliferation (P,0.001) and migration (P=0.010)
when compared with the vector control cells (Fig. 5B and 5C).
ILK expression correlated with phosphorylation of Akt
and GSK3b
Oncogenic Akt has been reported to be the main downstream
player of ILK signaling pathways [7]. In the physiological context,
it has been shown that ILK overexpression in HCC correlated
with Akt activation [14]. This inspired us to investigate the
involvement of Akt signaling in ILK-mediated oncogenic proper-
ties in HCC cells. BEL7402 ILK knockdown stable clones were
treated with insulin to stimulate phosphorylation of Akt and its
downstream effector GSK3b. In untreated cells, western blot
analysis revealed higher pAkt Serine-473 and pGSK3b levels in
NT control clone when compared to E5 and E6 stable clone.
Upon insulin stimulation, the pAkt Serine-473 and pGSK3b levels
were greatly elevated in NT control clone, but only increased
marginally in E5 and E6 stable clones (Fig. 6). In accordance with
the inhibition of Akt phosphorylation in ILK knockdown clones,
pAkt Serine-473 expression level was also suppressed in tumors
formed in subcutaneous injection (Fig. 4D). Conversely, overex-
ILK is Oncogenic in HCC
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pGSK3b; however, pAkt Serine-473 was not even detected in
the parental PLC cells. (Fig. 5D). Consistently, ILK overexpres-
sion induced upregulation of pAkt Serine-473 and pGSK3b levels
in HEK293T cells. This implicated that ILK regulates the activity
of Akt and which in turn exerts its functional effects in HCC cells.
Discussion
Expression of ILK was found to be elevated in many human
cancers. Correlation between ILK expression with tumor stage
and patient survival has been reported in various malignancies
including prostate cancer, colon cancer and ovarian cancer
Figure 3. ILK knockdown inhibited cell migration and invasion. (A) Cells from BEL7402 and HLE ILK knockdown stable clones were grown to
confluence and a wound was created. Closure of the wound was monitored and captured 16 hours after the wound was made. (B) BEL7402 and HLE
ILK knockdown stable clones were seeded onto migration chambers in triplicate and were allowed to migrate for 24 hours. Cells migrated through
the membrane were fixed and visualized by crystal violet staining. (C) ILK knockdown stable clones were seeded onto matrigel-coated invasion
chamber. BEL7402 was allowed to migrate for 72 hours while HLE required only 24 hours to invade. Cells were fixed, stained and scored. *P,0.05 and
**P,0.001 were regarded as statistically significant.
doi:10.1371/journal.pone.0016984.g003
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carcinoma and retinoblastoma revealed a decrease or no ILK
expression in tumor tissues [15,16]. Such heterogeneous expres-
sion pattern of ILK in human cancers may suggest tissue or organ-
specific functions of ILK. Expression of ILK in human HCC has
been examined and reported to be overexpressed [13,14]. ILK
overexpression was neither correlated with tumor grade nor
patient survival. In this study, 57 cases of paired HCC and non-
tumorous liver samples were subjected to qPCR analysis to assess
the level of ILK mRNA. These cases were randomly selected
which involved samples ranging from stage I to stage IV HCC.
Here, we report that ILK was found to be overexpressed with at
least two-fold in 37% of the cases. More important, a stepwise
increase in ILK expression was revealed along tumor progression.
ILK expression in either cirrhotic liver or stage I tumor was
significantly lower than the advanced stage IV tumor.
In spite of the potential significance of ILK in hepatocarcino-
genesis, functional role of ILK and elucidation of its associated
pathways in HCC have not been clearly defined. Demonstration
of its oncogenic activity in HCC is still lacking. To understand the
functions of ILK, the endogenous ILK expression in two HCC cell
lines was silenced by shRNA. Cell properties of the ILK-depleted
cells were then analyzed and compared with the control cells in
various functional assays. In both HCC cell lines, ILK knockdown
stable clones displayed suppressed cell proliferation and anchorage
independent growth. Besides, motility and invasiveness of cells
were largely impeded upon ILK depletion. Our study has also
provided the first validation about the functional loss of ILK
expression in vivo. HCC cells with the suppressed ILK expression
displayed inhibited ability to form tumors in nude mice. Notably,
the results of functional assays indeed correlated very well with
ILK knockdown efficiency. All these studies affirmed our findings
that ILK exerts oncogenic effect on HCC cell lines and the extent
of the effect depends highly on the degree of ILK expression in
cells.
Phosphorylation of the pro-survival protein kinase B (PKB)/Akt
at the serine 473 position in a phosphatidylinositol 3-kinase
(PI3K)-dependent manner by ILK has been well established [7].
Persistent activation of Akt signaling cascade is prominent in
various human cancers. Indeed, ILK/Akt pathway has been
shown to be involved in breast cancer, prostate cancer and glioma
[17,18,19]. Being the central player of signaling network, Akt is
involved in diverse pathways and various physiological roles.
Activation of the PKB/Akt pathway has been shown to induce cell
survival, resist apoptosis, stimulate angiogenesis and enhance cell
invasiveness of cancer cells [7,20]. All these promoted growth and
migratory capacities further facilitate tumor growth and progres-
sion. Due to the significance of PKB/Akt pathway on tumorigen-
esis and the well established link between ILK and Akt in other
cancers, the involvement of Akt in ILK-mediated functional effect
was initiated. Our result showed that the expression level of pAkt
Serine-473 and pGSK3b were increased in NT control clone upon
insulin stimulation, indicating that insulin could successfully
activate Akt and GSK3b in BEL7402. On the contrary, the
Figure 4. ILK knockdown suppressed in vivo tumorigenicity in BEL7402. (A) ILK knockdown clones were injected subcutaneously into the
right flank of nude mice with 5610
6 cells per site. Volumes of the tumors were measured every week by the formula: V=K6a (length) x b
2 (width).( B)
Mice were sacrificed at the third week after subcutaneous injection. (C) Tumors were harvested, photographed and weighed. (D) Protein was
extracted from the excised tumors and analyzed for pAkt expression by western blotting. *P,0.05 was regarded as statistically significant.
doi:10.1371/journal.pone.0016984.g004
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16984Figure 5. ILK overexpression enhanced PLC cell growth and motility. (A) FLAG-tagged ILK was transduced into PLC cells and stable clone of
ILK was established. Western blot analysis confirmed stable FLAG-ILK expression in PLC cells but not in vector control clone. (B) PLC/vector and PLC/
FLAG-ILK cells were counted in triplicates for 8 consecutive days. (C) PLC ILK overexpressing cells were subjected to migration assay. Cells were
seeded in triplicates and allowed to migrate for 16 hours. Migrated cells were fixed and stained by crystal violet. (D) PLC and HEK293T cells
overexpressing ILK were collected for western blot analysis to study the phosphorylation of Akt and GSK3b. Expression of b-actin was included as an
internal loading control. *P,0.05 and **P,0.001 were regarded as statistically significant.
doi:10.1371/journal.pone.0016984.g005
Figure 6. ILK knockdown suppressed phosphorylation of Akt and GSK3b. Insulin was added to cells to stimulate the PKB/Akt signaling
pathway. Cell lysates were then collected for western blotting analysis. Expression levels of pAkt, total Akt, pGSK3b, total GSK3b and ILK were shown.
Expression of b-actin was included as an internal loading control. The band intensities were determined by densitometry, and the amount of pAkt
and pGSK3b was normalized with that of total Akt and GSK3b respectively.
doi:10.1371/journal.pone.0016984.g006
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16984enhancement in pAkt Serine-473 and pGSK3b levels were not
observed in the two ILK knockdown clones after insulin treatment.
Our findings clearly indicate that silencing of ILK suppressed Akt
phosphorylation and activation. On the other hand, enhanced
level of pGSK3b was observed in PLC ILK overexpressing stable
clone. Intriguingly, this implicated ILK-Akt signaling in HCC is
supported by the previous findings in which ILK overexpression
was strongly associated with the activation of Akt in HCC clinical
tissues [14].
Akt is the key downstream component of PI3K signaling
[21,22]. Recruitment of Akt from the cytoplasm to the plasma
membrane allows activation of Akt by phosphorylation of both
Thr308 and Ser473 [23]. Activated Akt has been shown to
phosphorylate and regulates a number of cellular proteins.
Glycogen-synthase kinase 3 was identified as the first substrate of
Akt followed by the subsequent identification of a number of
targets phosphorylated by Akt [24,25]. These substrates have been
involved in various cellular processes such as metabolism,
proliferation, differentiation, apoptosis, migration and invasion
[26,27]. Some downstream effectors of Akt have been shown to
play an indispensible role in HCC. For instance, PAK1 expression
was found to be elevated in about 75% of human HCCs [28]. Its
overexpression was associated with more aggressive tumor
behavior and poor prognosis. PAK1 overexpression and knock-
down resulted in enhance and inhibited cell motility and
invasiveness, respectively. Interestingly, study has shown that
PAK1 phosphorylates ILK and mediates its nucleocytoplasmic
shuttling and functions in the nucleus [29]. Another target of Akt is
RhoA, which has also been implicated in HCC. RhoA is a
member of the Ras superfamily of small GTPase. It plays
important role in the regulation of actin cytoskeleton and stress
fiber formation, as well as proper organization of focal adhesion
complexes. As a result, activation of RhoA is important for cell
migration and cell cycle progression [30]. Immunoblotting analysis
revealed a higher RhoA expression in 69.2% (18/26) of HCC
tumor tissues when compared with their adjacent non-tumorous
tissues. Active RhoA level was also elevated in HCC tissues
expressing high level of RhoA [31]. Higher expression of RhoA in
HCC tumors was found to have significant association with the
presence of venous invasion, microscopic satellite lesions, and
advanced pTNM stage [32]. Kakinuma et al. has shown that
constitutively active Akt increased the level of activated RhoA,
where cells pre-treated with LY294002, a PI3K inhibitor, showed
a dramatic decrease in active RhoA level [33]. Collectively, these
studies show that ILK is tightly associated with important
molecules which have been implicated in HCC tumourigenesis
and motility. It is possible that ILK-Akt signaling with these
important players might constitute important regulatory pathways
in HCC.
Materials and Methods
Cell culture, HCC cell lines and clinical samples
HCC cell lines SMMC7721 and BEL7402 were obtained from
the Shanghai Institute of Cell Biology, Chinese Academy of
Sciences, People’s Republic of China. Other human cell lines
including HEK293FT, HepG2, Huh7, Hep3B and PLC were
purchased from the American Type Culture Collection. H2P and
MIHA cell lines were generous gifts from XY Guan and ST Fan of
The University of Hong Kong respectively. Another HCC cell
line, HLE was obtained from the Japanese Collection of Research
Bioresources (JCRB, Japan) and was cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) low glucose medium
supplemented with 10% fetal bovine serum (FBS), penicillin and
streptomycin. HEK293FT cells were maintained in DMEM high
glucose medium and all the other cell lines were cultured in high
glucose DMEM supplemented with sodium pyruvate. All cell lines
were cultured in a humidified incubator at 37uC with 5% CO2 in
air.
Human HCC tumor samples and their non-tumorous counter-
parts were obtained from HCC patients having surgical resection
in Queen Mary Hospital. The clinicopathological parameters of
HCC samples are shown in Table 1. The resected tissues were
immediately snap-frozen in liquid nitrogen and stored at 280uC.
Written informed consent from patients and approval of the
human specimens used in this study was obtained by the
Institutional Review Board of The University of Hong Kong/
Hospital Authority Hong Kong West Cluster (HKU/HA HKW
IRB).
Protein extraction and western blot analysis
Proteins were extracted from cells using NET-N lysis buffer
(25 mM Tris-HCl, pH 8.0, 50 mM NaCl, 0.2 mM EDTA, 0.1%
NP40) with the addition of a cocktail of protease inhibitor (Roche,
Mannheim, Germany). The cell lysate was cleared by centrifuga-
tion and the amount of protein was determined by Bradford
Table 1. Summary of the clinicopathological characteristics
of HCC patients.
Parameters No. of patients (%)
Age
Mean (range)
Sex
Male
Female
54.2 (28–82 years)
45 (85)
8( 1 5 )
Venous invasion
Absent
Present
26 (51)
25 (49)
Tumor encapsulation
Absent
Present
29 (57)
22 (43)
Tumor microsatellite
Absent
Present
28 (55)
23 (45)
Hepatitis B surface antigen status
Negative
Positive
11 (22)
40 (78)
Resection margin
Negative
Positive
47 (92)
4( 8 )
Direct liver invasion
Absent
Present
28 (58)
20 (42)
Cellular differentiation
(Edmondson’s grading)
I-II
III-IV
28 (55)
23 (45)
Tumor size
,5c m
$5c m
18 (35)
33 (65)
Non-tumorous liver status
Normal and chronic hepatitis
Cirrhosis
22 (43)
29 (57)
Number of tumor nodule
1
$2
46 (90)
5( 1 0 )
doi:10.1371/journal.pone.0016984.t001
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electrophoresis and transferred to protein membrane (Amersham,
Little Chalfont, UK). Immunodetection was performed by the
ECL
TM detection system (GE Healthcare, Freiburg, Germany)
according to manufacturer’s instructions. The following antibodies
were used for western blotting. Anti-ILK1, anti-pAkt-Ser473, anti-
Akt and anti-pGSK3b antibodies were from Cell Signaling
Technology. Anti-GSK3b antibody was purchased from BD
Bioscience and anti-b-actin antibody was from Sigma-Aldrich.
The band intensity in the western blot was measured by
AlphaEase FC Software (Alpha Innotech Corporation, San
Leandro, CA).
Quantitative real-time RT-PCR
TaqmanH Gene Expression Assay (Applied Biosystems) specific
for ILK was used to detect the expression level of ILK in HCC
tumor samples using quantitative real time PCR (Assay ID:
Hs00177914_ml). A TaqmanH pre-developed assay reagent
(Applied Biosystems) was used to determine the expression level
of a housekeeping gene hypoxanthine ribosyltransferase (HPRT)
(Assay ID:Hs99999909_ml), which was used for normalization.
The quantitative PCR was performed according to manufacturer’s
manual and described elsewhere [34].
ILK knockdown and overexpression stable clones
establishment by lentiviral-based system
MISSIONH Lentiviral shRNA knockdown system (Sigma-
Adrich, St. Louis, MO) was used to knockdown ILK expression
(NM_004517) in BEL7402 and HLE cells. Four shILK sequences
were designed, namely E5, E6, E7 and E8. Preparation of viral
supernatant was prepared according to manufacturer’s instructions.
In brief, shILK lentiviral vectors which pre-mixed with MISSIONH
lentiviral packaging mix (Sigma-Aldrich, St. Louis, MO) were
transfected into 293FT cells using FuGENEH 6 transfection reagent
(Roche Diagnostics GmbH, Germany). Twenty-four hours after
transfection, viral particles containing the shILK sequence were
rapidly produced and released to the culture medium. The medium
containing viral particles were collected for infection or stored at
280uC for future use. For viral infection of HCC cells, viral
supernatant was added to the cells.Polybrenewasadded to enhance
the infection efficiency. Twenty-four hours after infection, the viral
supernatant was removed and replaced with full medium. Cells
were then cultured in puromycin (Calbiochem) containing medium
to select for the positively-infected cells. To establish ILK
overexpressing stable clone in PLC cells, pLenti6/V5-D-TOPO
plasmid carrying FLAG-ILK and MISSIONH Lentiviral Packaging
mix were transfected into 293FT cells. Viral supernatant was
collected and used to induce PLC cells. Transduced PLC cells were
then selected by blasticidin (Invitrogen).
Cell proliferation assay
To assess cell proliferation of each cell line, a growth curve was
determined by seeding 10,000 cells on each well of a 12-well tissue
culture plate and counting the number of cells in triplicate for five
to eight consecutive days.
Soft agar colony formation assay
Bottom agar (1 g agar, 30 of ml water, 50 ml of 26 DMEM,
20 ml of FBS) was equilibrated in a 55uC water bath while top
agar (0.2 g agar, 15 ml of water, 25 ml of 26DMEM, 10 ml of
FBS) was put in a 45uC water bath. Five ml of bottom agar was
added to each 60-mm tissue culture plate and was allowed to set at
room temperature. A cell suspension of 8610
4 cells in 8 ml of top
agar was prepared and 2 ml of it was added per 60-mm tissue
culture plate pre-coated with 5 ml of bottom agar. After the agar
was set, the plates were wrapped with parafilm and incubated at
37uC for three to four weeks to allow the formation of colonies. At
the end of incubation, pictures of colonies formed in each plate
were taken at three different views. Number of colonies and the
size of them were then counted and measured.
Wound-healing assay
HCC cells were seeded onto 6-well tissue culture plate until
reaching 100% confluence. Mitomycin C (Calbiochem) at a
concentration of 10 mg/ml was used to treat cells for 3 hours to
inhibit cell proliferation. A wound was created by scratching the cell
surface with a 10 ml pipette tip. Images of the wound were captured
every 16, 24, 48 and 72 hours to observe the rate of wound closure.
Cell migration and invasion assay
Cells were pretreated with mitomycin C (Calbiochem) for
3 hours to inhibit cell proliferation before subjected to migration
and invasion assays. TranswellH (Corning) chamber was used to
perform cell migration assay. To each chamber, 5610
4 cells were
seeded and full medium was added to the bottom chamber as a
chemo-attractant to the cells. For invasion assay, 5610
5 cells were
seeded to each BD BioCoat
TM Matrigel
TM Invasion Chamber (BD
Biosciences). For both assays, cells were allowed to migrate or
invade. After incubation, cells on the upper side of the membrane
were removed by cotton swab, while those at the bottom were fixed
and stained with crystal violet. Numbers of cells migrated and
invaded were counted. The assays were performed in triplicates.
The detailed procedure has been described in previous studies [35].
Nude mice subcutaneous injection
A cell suspension of 100 mlo f1 6 PBS containing 5610
6 cells
was injected subcutaneously into the right flank of nude mice.
Each experimental group was tested in a group of 5 mice. Size of
the tumor formed was monitored closely and was measured every
week using a caliper. Volumes of tumors were estimated according
the formula: Volume =K6a6b
2, where (a) and (b) represented the
largest and smallest diameters respectively. Mice were sacrificed
when the tumor size was larger than 1 cm61 cm. Tumors were
harvested, weighed and photographed. The animal work was
performed according to the Animals (Control of Experiments)
Ordinance (Hong Kong) and followed the University’s guidelines
on animal experimentation. The research protocol (CULATR
1749-08) was approved by the Committee on the Use of Live
Animals in Teaching and Research (CULATR) of the University.
Statistical analysis
ILK expression level in tumor and non-tumorous liver tissues
and the expression of ILK in different stages of HCC tumors were
compared using the paired and unpaired t-test, respectively.
Student t-test was used as the statistical method to determine the
difference in result distribution among cell groups in functional
assays. The t-test could only compare a pair of cell lines at a time.
All the above statistical analyses were performed by GraphPad
Prism 3.00 (San Diego, California, USA). A P-value less than 0.05
is considered as statistically significant.
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